CN100457753C - 依赖细胞周期蛋白的激酶的n－[5－[[[5－烷基－2－唑基]甲基]硫代]－2－噻唑基]甲酰胺抑制剂 - Google Patents

依赖细胞周期蛋白的激酶的n－[5－[[[5－烷基－2－唑基]甲基]硫代]－2－噻唑基]甲酰胺抑制剂 Download PDF

Info

Publication number
CN100457753C
CN100457753C CNB018133673A CN01813367A CN100457753C CN 100457753 C CN100457753 C CN 100457753C CN B018133673 A CNB018133673 A CN B018133673A CN 01813367 A CN01813367 A CN 01813367A CN 100457753 C CN100457753 C CN 100457753C
Authority
CN
China
Prior art keywords
compound
methyl
oxazolyl
thiazolyl
prepare
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018133673A
Other languages
English (en)
Chinese (zh)
Other versions
CN1444584A (zh
Inventor
R·N·米斯拉
H·-Y·肖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/727,957 external-priority patent/US6515004B1/en
Priority claimed from US09/746,060 external-priority patent/US6414156B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN1444584A publication Critical patent/CN1444584A/zh
Application granted granted Critical
Publication of CN100457753C publication Critical patent/CN100457753C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB018133673A 2000-07-26 2001-05-09 依赖细胞周期蛋白的激酶的n－[5－[[[5－烷基－2－唑基]甲基]硫代]－2－噻唑基]甲酰胺抑制剂 Expired - Fee Related CN100457753C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US61662700A 2000-07-26 2000-07-26
US09/616,627 2000-07-26
US09/727,957 2000-12-01
US09/727,957 US6515004B1 (en) 1999-12-15 2000-12-01 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US09/746,060 US6414156B2 (en) 1998-10-21 2000-12-22 Process for preparing azacycloalkanoylaminothiazoles
US09/746,060 2000-12-22

Publications (2)

Publication Number Publication Date
CN1444584A CN1444584A (zh) 2003-09-24
CN100457753C true CN100457753C (zh) 2009-02-04

Family

ID=27417184

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018133673A Expired - Fee Related CN100457753C (zh) 2000-07-26 2001-05-09 依赖细胞周期蛋白的激酶的n－[5－[[[5－烷基－2－唑基]甲基]硫代]－2－噻唑基]甲酰胺抑制剂

Country Status (26)

Country Link
EP (1) EP1303513A1 (enExample)
JP (1) JP2004509857A (enExample)
KR (1) KR20030016429A (enExample)
CN (1) CN100457753C (enExample)
AR (1) AR030563A1 (enExample)
AU (1) AU2001259704A1 (enExample)
BG (1) BG65132B1 (enExample)
BR (1) BR0112674A (enExample)
CA (1) CA2417254A1 (enExample)
CZ (1) CZ2003237A3 (enExample)
EE (1) EE200300041A (enExample)
EG (1) EG24409A (enExample)
GE (1) GEP20043367B (enExample)
HR (1) HRP20030116A2 (enExample)
HU (1) HUP0303698A2 (enExample)
IL (2) IL153591A0 (enExample)
LV (1) LV13037B (enExample)
MX (1) MXPA03000774A (enExample)
MY (1) MY129635A (enExample)
NO (1) NO20030394L (enExample)
PL (1) PL365170A1 (enExample)
SI (1) SI21099A (enExample)
SK (1) SK18392002A3 (enExample)
TW (1) TWI302533B (enExample)
WO (1) WO2002010162A1 (enExample)
YU (1) YU4903A (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
EP2311818B1 (en) * 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
AR038703A1 (es) 2002-02-28 2005-01-26 Novartis Ag Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
EP1545533A1 (en) 2002-09-04 2005-06-29 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
RU2380369C9 (ru) 2002-09-04 2011-07-10 Шеринг Корпорейшн Новые пиразолопиримидины как ингибиторы циклин-зависимой киназы
JP4799864B2 (ja) 2002-09-23 2011-10-26 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのイミダゾピラジン
KR20060010709A (ko) 2002-09-23 2006-02-02 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 신규한 이미다조피라진
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
EP1555264A1 (en) * 2004-01-15 2005-07-20 Sireen AG Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase.
DE102005008310A1 (de) * 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
EP1928865A1 (en) * 2005-08-17 2008-06-11 Schering Corporation Novel high affinity thiophene-based and furan-based kinase ligands
CA2621983A1 (en) 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
PE20070543A1 (es) 2005-10-06 2007-06-14 Schering Corp Pirazolopirimidinas como inhibidores de protein quinasas
JP2009539846A (ja) * 2006-06-06 2009-11-19 ブリストル−ミエルス スクイッブ カンパニー Ｎ−［５−［［［５−（１，１−ジメチルエチル）−２−オキサゾリル］メチル］チオ］−２−チアゾリル］−４−ピペリジンカルボキサミドの結晶形
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
EP2078003B1 (en) 2006-10-31 2017-03-08 Merck Sharp & Dohme Corp. Anilinopiperazine derivatives and methods of use thereof
KR20090082440A (ko) 2006-10-31 2009-07-30 쉐링 코포레이션 단백질 키나제 억제제로서의 2-아미노티아졸-4-카복실산 아미드
CA2686848A1 (en) 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
EP2470183B1 (en) 2009-08-26 2015-09-16 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
ES2685709T3 (es) 2012-03-30 2018-10-10 Merck Sharp & Dohme Corp. Biomarcador predictivo mediado por un inhibidor de CDK útil para la terapia contra el cáncer
EP3078671A4 (en) * 2013-12-04 2017-05-31 Hangzhou Minsheng Institutes for Pharma Research Co., Ltd. Gemcitabine derivative, composition containing the derivative and pharmaceutical use of the derivative

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024416A1 (en) * 1997-11-12 1999-05-20 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
AU768751B2 (en) * 1998-06-18 2004-01-08 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6414156B2 (en) * 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
MY125768A (en) * 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024416A1 (en) * 1997-11-12 1999-05-20 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases

Also Published As

Publication number Publication date
SI21099A (sl) 2003-06-30
LV13037B (en) 2003-11-20
BG107468A (en) 2004-01-30
TWI302533B (en) 2008-11-01
JP2004509857A (ja) 2004-04-02
BG65132B1 (bg) 2007-03-30
CN1444584A (zh) 2003-09-24
HRP20030116A2 (en) 2005-02-28
SK18392002A3 (sk) 2003-09-11
KR20030016429A (ko) 2003-02-26
GEP20043367B (en) 2004-06-10
IL153591A0 (en) 2003-07-06
YU4903A (sh) 2006-03-03
CA2417254A1 (en) 2002-02-07
AU2001259704A1 (en) 2002-02-13
IL153591A (en) 2009-07-20
NO20030394D0 (no) 2003-01-24
EE200300041A (et) 2005-04-15
NO20030394L (no) 2003-03-03
EG24409A (en) 2009-05-20
MXPA03000774A (es) 2003-09-10
CZ2003237A3 (cs) 2003-06-18
PL365170A1 (en) 2004-12-27
MY129635A (en) 2007-04-30
HUP0303698A2 (hu) 2004-04-28
EP1303513A1 (en) 2003-04-23
BR0112674A (pt) 2003-12-30
WO2002010162A1 (en) 2002-02-07
AR030563A1 (es) 2003-08-27

Similar Documents

Publication Publication Date Title
US6515004B1 (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
KR100738132B1 (ko) 사이클린 의존성 키나제의ｎ-[5-[[[5-알킬-2-옥사졸릴]메틸]티오]-2-티아졸릴]-카르복스아미드 억제제
ZA200204349B (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases.
CN1444584A (zh) 依赖细胞周期蛋白的激酶的n－[5－[[[5－烷基－2－噁唑基]甲基]硫代]－2－噻唑基]甲酰胺抑制剂
US6107305A (en) Use of pyrazolo [3,4-b] pyridine as cyclin dependent kinase inhibitors
CZ20022013A3 (cs) N-[5-[[[5-Alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]karboxamidové inhibitory cyklin-dependentních kinas
TW201350478A (zh) Ｎａｍｐｔ抑制劑
CA2399274A1 (en) 3-aminopyrazole inhibitors of cyclin dependent kinases
LT5106B (lt) Nuo ciklinų priklausomų kinazių n-[5-[[[5-alkil-2-oxazolil]metil]tio]-2-tiazolil]karboksamido inhibitoriai
ZA200300452B (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases.
KR100406634B1 (ko) 3,5-디아미노인다졸 유도체, 그의 제조방법 및 사이클린의존성 키나아제 저해제로서의 그의 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090204

Termination date: 20100509